company background image
SRT

Sartorius XTRA:SRT Stock Report

Last Price

€326.50

Market Cap

€22.5b

7D

6.5%

1Y

-23.2%

Updated

28 Jun, 2022

Data

Company Financials +
SRT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance5/6
Financial Health4/6
Dividends0/6

SRT Stock Overview

Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide.

Sartorius Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sartorius
Historical stock prices
Current Share Price€326.50
52 Week High€834.00
52 Week Low€276.50
Beta0.40
1 Month Change-5.09%
3 Month Change-6.18%
1 Year Change-23.18%
3 Year Change100.31%
5 Year Change288.74%
Change since IPO30,156.22%

Recent News & Updates

Jun 24
Why The 23% Return On Capital At Sartorius (ETR:SRT) Should Have Your Attention

Why The 23% Return On Capital At Sartorius (ETR:SRT) Should Have Your Attention

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...

Jun 06
If You Like EPS Growth Then Check Out Sartorius (ETR:SRT) Before It's Too Late

If You Like EPS Growth Then Check Out Sartorius (ETR:SRT) Before It's Too Late

Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...

Mar 28
Here's Why Sartorius (ETR:SRT) Can Manage Its Debt Responsibly

Here's Why Sartorius (ETR:SRT) Can Manage Its Debt Responsibly

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

Shareholder Returns

SRTDE Medical EquipmentDE Market
7D6.5%7.6%-0.5%
1Y-23.2%-16.3%-21.1%

Return vs Industry: SRT underperformed the German Medical Equipment industry which returned -16.3% over the past year.

Return vs Market: SRT underperformed the German Market which returned -21.1% over the past year.

Price Volatility

Is SRT's price volatile compared to industry and market?
SRT volatility
SRT Average Weekly Movement6.4%
Medical Equipment Industry Average Movement6.5%
Market Average Movement5.6%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.9%

Stable Share Price: SRT is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: SRT's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
187015,051Joachim Kreuzburghttps://www.sartorius.com

Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products.

Sartorius Fundamentals Summary

How do Sartorius's earnings and revenue compare to its market cap?
SRT fundamental statistics
Market Cap€22.51b
Earnings (TTM)€434.19m
Revenue (TTM)€3.68b

51.4x

P/E Ratio

6.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SRT income statement (TTM)
Revenue€3.68b
Cost of Revenue€1.72b
Gross Profit€1.96b
Other Expenses€1.53b
Earnings€434.19m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Jul 21, 2022

Earnings per share (EPS)6.35
Gross Margin53.20%
Net Profit Margin11.79%
Debt/Equity Ratio98.7%

How did SRT perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

20%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is SRT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SRT?

Other financial metrics that can be useful for relative valuation.

SRT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue6.7x
Enterprise Value/EBITDA20.7x
PEG Ratio6.1x

Price to Earnings Ratio vs Peers

How does SRT's PE Ratio compare to its peers?

SRT PE Ratio vs Peers
The above table shows the PE ratio for SRT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average33x
SHL Siemens Healthineers
28.2x12.8%€53.5b
AFX Carl Zeiss Meditec
38.7x9.2%€10.2b
SBS Stratec
27.4x13.3%€1.1b
DRW3 Drägerwerk KGaA
37.5x43.5%€863.7m
SRT Sartorius
51.4x8.4%€22.5b

Price-To-Earnings vs Peers: SRT is expensive based on its Price-To-Earnings Ratio (51.4x) compared to the peer average (33x).


Price to Earnings Ratio vs Industry

How does SRT's PE Ratio compare vs other companies in the European Medical Equipment Industry?

Price-To-Earnings vs Industry: SRT is expensive based on its Price-To-Earnings Ratio (51.4x) compared to the German Medical Equipment industry average (28.3x)


Price to Earnings Ratio vs Fair Ratio

What is SRT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SRT PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio51.4x
Fair PE Ratio28.7x

Price-To-Earnings vs Fair Ratio: SRT is expensive based on its Price-To-Earnings Ratio (51.4x) compared to the estimated Fair Price-To-Earnings Ratio (28.7x).


Share Price vs Fair Value

What is the Fair Price of SRT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SRT (€326.5) is trading above our estimate of fair value (€229.27)

Significantly Below Fair Value: SRT is trading above our estimate of fair value.


Price to Earnings Growth Ratio

PEG Ratio: SRT is poor value based on its PEG Ratio (6.1x)


Discover undervalued companies

Future Growth

How is Sartorius forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?

Future Growth Score

4/6

Future Growth Score 4/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


8.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SRT's forecast earnings growth (8.4% per year) is above the savings rate (-0.05%).

Earnings vs Market: SRT's earnings (8.4% per year) are forecast to grow faster than the German market (8.3% per year).

High Growth Earnings: SRT's earnings are forecast to grow, but not significantly.

Revenue vs Market: SRT's revenue (9.6% per year) is forecast to grow faster than the German market (4.8% per year).

High Growth Revenue: SRT's revenue (9.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SRT's Return on Equity is forecast to be high in 3 years time (25%)


Discover growth companies

Past Performance

How has Sartorius performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


29.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SRT has a large one-off loss of €253.0M impacting its March 31 2022 financial results.

Growing Profit Margin: SRT's current net profit margins (11.8%) are higher than last year (10%).


Past Earnings Growth Analysis

Earnings Trend: SRT's earnings have grown significantly by 29% per year over the past 5 years.

Accelerating Growth: SRT's earnings growth over the past year (65.5%) exceeds its 5-year average (29% per year).

Earnings vs Industry: SRT earnings growth over the past year (65.5%) exceeded the Medical Equipment industry 1.3%.


Return on Equity

High ROE: SRT's Return on Equity (29.4%) is considered high.


Discover strong past performing companies

Financial Health

How is Sartorius's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: SRT's short term assets (€1.9B) exceed its short term liabilities (€1.5B).

Long Term Liabilities: SRT's short term assets (€1.9B) do not cover its long term liabilities (€2.4B).


Debt to Equity History and Analysis

Debt Level: SRT's net debt to equity ratio (86.2%) is considered high.

Reducing Debt: SRT's debt to equity ratio has reduced from 117.7% to 98.7% over the past 5 years.

Debt Coverage: SRT's debt is well covered by operating cash flow (42.6%).

Interest Coverage: SRT earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Sartorius's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


0.38%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: SRT's dividend (0.38%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.45%).

High Dividend: SRT's dividend (0.38%) is low compared to the top 25% of dividend payers in the German market (4.5%).


Stability and Growth of Payments

Stable Dividend: SRT is not paying a notable dividend for the German market, therefore no need to check if payments are stable.

Growing Dividend: SRT is not paying a notable dividend for the German market, therefore no need to check if payments are increasing.


Earnings Payout to Shareholders

Earnings Coverage: SRT is not paying a notable dividend for the German market.


Cash Payout to Shareholders

Cash Flow Coverage: SRT is not paying a notable dividend for the German market.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.3yrs

Average management tenure


CEO

Joachim Kreuzburg (56 yo)

19.58yrs

Tenure

€2,585,000

Compensation

Dr. rer. pol. Joachim Kreuzburg serves as the Chairman and Chief Executive Officer at Sartorius Stedim Biotech GmbH.Dr. rer. pol. Kreuzburg has been the Chairman of Executive Board at Sartorius Aktiengese...


CEO Compensation Analysis

Compensation vs Market: Joachim's total compensation ($USD2.72M) is below average for companies of similar size in the German market ($USD5.66M).

Compensation vs Earnings: Joachim's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: SRT's management team is seasoned and experienced (5.3 years average tenure).


Board Members

Experienced Board: SRT's board of directors are considered experienced (5.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Sartorius Aktiengesellschaft's employee growth, exchange listings and data sources


Key Information

  • Name: Sartorius Aktiengesellschaft
  • Ticker: SRT
  • Exchange: XTRA
  • Founded: 1870
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: €22.505b
  • Shares outstanding: 68.42m
  • Website: https://www.sartorius.com

Number of Employees


Location

  • Sartorius Aktiengesellschaft
  • Otto-Brenner-Strasse 20
  • Göttingen
  • Lower Saxony
  • 37079
  • Germany

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/28 00:00
End of Day Share Price2022/06/28 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.